CorMedix Shares Gain After 1Q Preliminary Sales Beat Views

Dow Jones

04/08

By Katherine Hamilton

CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations.

Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year.

The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million.

CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million.

The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 08, 2025 10:14 ET (14:14 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2525681668"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525681668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525681668?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525681668","market":"sg","top_or_hot":-1,"title":"CorMedix Shares Gain After 1Q Preliminary Sales Beat Views","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n</p>\n<p>\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n</p>\n<p>\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n</p>\n<p>\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n</p>\n<p>\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Gain After 1Q Preliminary Sales Beat Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Gain After 1Q Preliminary Sales Beat Views\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-08 22:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n</p>\n<p>\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n</p>\n<p>\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n</p>\n<p>\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n</p>\n<p>\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525681668","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525681668","pubTimestamp":1744121640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations.Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year.The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million.CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million.The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"第一季度初步销售额超出预期后CorMedix股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  CorMedix shares rose after the company's preliminary first-quarter revenue figure came in above expectations. \n\n\n  Shares climbed 16.5% to $7.07 Tuesday. The stock is down 14.1% so far this year. \n\n\n  The Berkeley Heights, N.J., biopharmaceutical company recorded preliminary first-quarter revenue of $39 million, it said Tuesday. Analysts polled by FactSet were forecasting $32.3 million. \n\n\n  CorMedix also increased first-half guidance for sales to existing purchasing customers to between $62 million and $70 million. \n\n\n  The company said it received larger-than-expected orders during the final week of March. It also has more visibility into inventory levels on hand at some current purchasing customers, it said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 10:14 ET (14:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}